Search results: (10000)
News Results of Knee and Hip Joint Arthroplasty in Hemophiliacs
Total endoprosthesis implantation represents an effective solution for the terminal stages of joint degeneration in hemophiliacs. However, compared to the general population, this group of patients exhibits certain specificities, a higher rate of complications, and historically worse surgical outcomes. Recent studies show that with advancements in surgical techniques, implants, and perioperative care, the results are approaching those of the population without a history of bleeding disorders.
News Manual Fascial Therapy in Patients with Hemophilic Arthropathy
Fascial therapy is a rehabilitative technique that mobilizes the fascial complex using manual techniques with the goal of improving tissue mobility and function, as well as influencing pain. A team of experts from Spain evaluated the safety of this method in hemophiliacs with developed arthropathy in their study.
News Safety Analysis of Baricitinib in Long-Term Treatment of Rheumatoid Arthritis
Janus kinase inhibitors are relatively new and very promising drugs, but their novelty also raises the question: Are they really safe? A brand-new analysis provides the answer by examining a cohort of patients treated for the longest duration to date.
News Impact of Antiemetic Prophylaxis on Quality of Life of Patients Treated with Chemotherapy – Data from Practice
Chemotherapy-induced nausea and vomiting (CINV) is a relatively common complication of cancer treatment with a significantly negative impact on patients' quality of life. A large prospective analysis of real-world clinical practice data was conducted in Germany, examining the efficacy and safety of treatment with the oral combination of netupitant and palonosetron and the impact of this therapy on patients' quality of life.
News Individualized Prophylaxis with Achieving Higher Minimum Levels as a Possible Path to Optimal Treatment of Hemophilia A
Prophylactic administration of factor VIII (FVIII) concentrate is the standard of care for individuals with severe hemophilia A. Traditionally, the goal of prophylaxis has been to maintain minimum FVIII levels > 1%. However, it has been shown that this goal may not protect many hemophiliacs from bleeding episodes. So how does prophylaxis that maintains higher FVIII levels stand? These insights were brought by the PROPEL study, whose results were recently published in Blood magazine.
News fSCIG in Elderly Patients with PID or SID in Real Clinical Practice
The work of a team of German and Dutch authors presents data on the real clinical use of 10% subcutaneous immunoglobulin facilitated by hyaluronidase (fSCIG) in elderly patients with primary (PID) or secondary (SID) immunodeficiency.
News An Introductory Word to the Section on Hereditary Angioedema — MUDr. Roman Hakl, Ph.D.
Hereditary angioedema (HAE) is a genetically conditioned disease, currently classified into HAE with C1 inhibitor deficiency (HAE-C1-INH), referred to as HAE-I and HAE-II, and HAE with normal level and function of C1 inhibitor (HAE nC1-INH), also referred to as HAE-III (1).
News Tofacitinib Through the Eyes of Patients: Rapid Response After Treatment Initiation
How does tofacitinib fare in the treatment of ulcerative colitis in real clinical practice from the patients' perspective? This was addressed in a recent study published in the journal Inflammatory Bowel Diseases.
News Does Peritoneal Dialysis Have Its Place Even in Acute Cases?
In patients who urgently need to replace kidney function, hemodialysis traditionally played the role of the gold standard. Can peritoneal dialysis fully replace it?
News Efficacy and Safety of Fenfluramine in the Treatment of Lennox-Gastaut Syndrome – An Overview of Current Knowledge
In a recently published article, British authors summarize the current knowledge on the efficacy and safety of fenfluramine (FFA) in the treatment of Lennox-Gastaut syndrome (LGS, a developmental and epileptic encephalopathy). In addition to the reduction in seizure frequency demonstrated in clinical studies, they discuss the impact of fenfluramine on reducing the risk of sudden unexpected death in epilepsy (SUDEP), improving cognitive function in patients, and its safety concerning weight loss and heart disorders.
News Pain Management in Patients After Hip and Knee Arthroplasty – Data from Clinical Practice
Inadequate analgesia after hip and knee arthroplasty can result in delayed postoperative recovery accompanied by chronic pain. The retrospective study presented below compared the efficacy of analgesia via continuous epidural infusion of ropivacaine, patient-controlled IV analgesia with the so-called Würzburg drip, and piritramide.
News Digital Technology in COPD Therapy: Current Options and Future Prospects
This year, digital technologies have demonstrated their advantages in interpersonal communication, administrative processes, and in the field of medicine. The global crisis triggered by the coronavirus pandemic revealed the need to implement telemedicine into everyday medical practice. What are its options and future prospects in the therapy of patients with chronic obstructive pulmonary disease? These questions are thoroughly addressed in an article published in the Journal of Thoracic Disease last fall.
News Another Positive Effect of Diosmin − Influence on Oxidative Stress
Diosmin is an established drug in the therapy of chronic venous insufficiency. It is known to act through several different mechanisms. A study by Polish authors provides evidence of its ability to reduce oxidative stress.
News Combination of Targeted Therapy with Chemo in 1st Line in Patients with Left-Sided wtRAS mCRC
The preferred targeted therapy added to the combination with standard chemotherapy (CHT) for left-sided metastatic colorectal cancer (mCRC) with non-mutated RAS oncogene should be an antibody against the epidermal growth factor receptor (anti-EGFR), not against the vascular endothelial growth factor (anti-VEGF). This is based on a direct comparison of anti-EGFR panitumumab and anti-VEGF bevacizumab in the Japanese phase III PARADIGM study. The results were presented at the ASCO 2022 annual meeting.
News Non-factor vs. Factor Prophylaxis of Hemophilia A: A Comparison of Cost and Treatment Effectiveness Based on Real-World Data from the USA
In the prophylactic treatment of patients with hemophilia A, particularly its severe form, concentrates of clotting factor VIII (FVIII) with extended half-life (EHL) are increasingly administered, or non-factor treatment, represented in clinical practice by FVIII mimetic antibody emicizumab. However, insights into the direct comparison of effectiveness and economic burden arising from prophylaxis with these modalities are limited, including data from real-world practice. One recently published study therefore attempted to conduct such a retrospective comparison based on data from healthcare-related databases in the USA.
News Is Six Months of Adjuvant Targeted Therapy Sufficient for Early Breast Cancer?
The inclusion of adjuvant targeted therapy with chemotherapy for early HER2-positive breast cancer significantly improved patient outcomes. Since 2006, based on data from registration studies, the gold standard for adjuvant therapy has been 12 months of trastuzumab administration. However, similar effects were observed in a smaller study with just 9 weeks of treatment. The presented clinical trial therefore investigated the non-inferiority of shorter treatment duration (6 months).
News Mental Health During the Pandemic − and How to Alleviate Its Impacts
At the symposium during the XV Spring Interactive Conference of the General Medical Society of ČLS JEP, which was eventually held in September 2021 in Prague, Prof. MUDr. Cyril Höschl, DrSc., FRCPsych, presented his lecture on the impacts of the COVID-19 pandemic on mental health. At the end of his speech, he also addressed the practical issue of selecting a suitable antidepressant.
News Recommendations for Lipid Administration in Patients on Home Parenteral Therapy
Home parenteral therapy is an important part of treatment for patients with chronic intestinal failure who cannot achieve adequate nutrition through enteral feeding. An integral component of this therapy is lipid emulsion, which provides a source of energy and essential fatty acids. However, long-term administration of lipid emulsion may be associated with liver damage. According to available studies, the risk can be reduced by adjusting the dosage of lipid emulsion and preferring emulsions without soybean oil.
News Current Data on the Safety Profile of Baricitinib in the Treatment of Rheumatoid Arthritis
Baricitinib was approved for the treatment of rheumatoid arthritis (RA) in 2017, making it essential and relevant to monitor its safety profile in clinical practice. The analysis of data collected over 8.4 years presented below provides current insights.
News Administration of Romiplostim in Patients with ITP in Real-World Practice in Central Europe
Data from the PLATON study on the administration of romiplostim in real-world clinical practice in Central and Eastern Europe confirmed very good efficacy in patients with newly diagnosed, persistent, and chronic ITP.
News How to Prevent and Treat Thromboembolic Disease in Cancer Patients
Malignancy is one of the risk factors for the development of thromboembolic disease (TED). Venous thromboembolism is considered the second most common cause of death in cancer patients, with the top cause being the cancer itself. Therefore, optimal treatment and timely prevention of these complications is very important.
News How to Care for Dialysis Patients in the Times of COVID-19
More than 2 million people worldwide undergo maintenance hemodialysis in outpatient centers. Effective prevention of the spread of infection caused by the SARS-CoV-2 coronavirus within the care provided by hemodialysis centers is essential for the smooth provision of dialysis to patients with end-stage renal disease. The following work from experts in Boston is based on their experiences as well as recommendations from the American Society of Nephrology (ASN) and the Centers for Disease Control and Prevention (CDC).
News Safety and Efficacy of Different Antithrombotic Regimens in Patients with Atrial Fibrillation after Percutaneous Coronary Intervention
Patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) or after percutaneous coronary intervention (PCI) require antithrombotic therapy for the prevention of atherothrombosis, stent thrombosis, and cerebrovascular stroke (CVS). The meta-analysis presented below attempted to clarify which antithrombotic regimen is most suitable in terms of safety and efficacy for these patients.